To include your compound in the COVID-19 Resource Center, submit it here.

InterMune: Time to go global

Companies with clinical development experience are constantly trolling for compounds they can in-license to leverage those capabilities, but the market for quality compounds is tight.

InterMune Pharmaceuticals Inc. last week put a twist on this search by leveraging its ongoing clinical development program for Actimmune interferon gamma-Ib to

Read the full 487 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers